Literature DB >> 23994246

Comparing high and low total body irradiation dose rates for minimum-intensity conditioning of dogs for dog leukocyte antigen-identical bone marrow grafts.

Scott S Graves1, Barry E Storer, Tiffany M Butts, Rainer Storb.   

Abstract

We tested the hypothesis that total body irradiation (TBI) given at a high dose rate would be more immunosuppressive and lead to a higher incidence of stable hematopoietic cell engraftment after suboptimal levels of conditioning irradiation compared with TBI at a low dose rate. We assessed the engraftment success of dog leukocyte antigen-identical bone marrow transplantation in recipients of 100, 150, and 200 cGy TBI administered at a rate of 7 or 70 cGy/min. Dogs received donor marrow on the same day as TBI and were subsequently treated with postgraft immunosuppression consisting of mycophenolate mofetil (for 28 days) and cyclosporine (for 37 days). Donor chimerism was monitored until the end of study and was characterized by either graft rejection or stable engraftment. Increasing the radiation dose rate from the traditional 7 cGy/min to 70 cGy/min did not lead to increased engraftment success at any of the irradiation doses tested. The dose rate of 70 cGy/minute was no more hematotoxic than the rate of 7 cGy/minute. TBI delivered at a high dose rate was well tolerated but was not associated with a better rate of allogeneic hematopoietic cell engraftment compared with TBI delivered at a lower dose rate.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dog; Dose rate; Hematopoietic cell transplantation; Mixed chimerism; Nonmyeloablative conditioning regimen

Mesh:

Year:  2013        PMID: 23994246      PMCID: PMC3820284          DOI: 10.1016/j.bbmt.2013.08.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

1.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

2.  Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation.

Authors:  R Storb; R F Raff; T Graham; F R Appelbaum; H J Deeg; F G Schuening; G Sale; K Seidel
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

3.  Transplantation of allogeneic and xenogeneic (rat) marrow in irradiated mice as affected by radiation exposure rates.

Authors:  N Gengozian; D E Carlson; E M Allen
Journal:  Transplantation       Date:  1969-04       Impact factor: 4.939

Review 4.  Non-myeloablative transplants for malignant disease.

Authors:  R F Storb; R Champlin; S R Riddell; M Murata; S Bryant; E H Warren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

5.  DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing.

Authors:  J L Wagner; J D Works; R Storb
Journal:  Tissue Antigens       Date:  1998-10

6.  Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts.

Authors:  R Storb; R F Raff; F R Appelbaum; H J Deeg; T C Graham; F G Schuening; G Sale; E Bryant; K Seidel
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

7.  Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates.

Authors:  William J Hogan; Marie-Térèse Little; Eustacia Zellmer; Anke Friedetzky; Razvan Diaconescu; Serina Gisburne; Richard Lee; Christian Kuhr; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2003-08       Impact factor: 5.742

8.  Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.

Authors:  M S Thakar; P Kurre; R Storb; M Kletzel; H Frangoul; M A Pulsipher; W Leisenring; M E D Flowers; B M Sandmaier; A Woolfrey; H-P Kiem
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

9.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers.

Authors:  J L Wagner; R C Burnett; S A DeRose; L V Francisco; R Storb; E A Ostrander
Journal:  Transplantation       Date:  1996-09-27       Impact factor: 4.939

10.  Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting.

Authors:  C Yu; E Ostrander; E Bryant; R Burnett; R Storb
Journal:  Transplantation       Date:  1994-09-27       Impact factor: 4.939

View more
  5 in total

1.  Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Scott S Graves; Maura H Parker; Rainer Storb
Journal:  ILAR J       Date:  2018-12-31

2.  Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.

Authors:  Melinda Mata; Juan F Vera; Claudia Gerken; Cliona M Rooney; Tasha Miller; Catherine Pfent; Lisa L Wang; Heather M Wilson-Robles; Stephen Gottschalk
Journal:  J Immunother       Date:  2014-10       Impact factor: 4.456

Review 3.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

4.  Total Body Irradiation and Total Skin Irradiation Techniques in Belgium and the Netherlands: Current Clinical Practice.

Authors:  Phil W Koken; Lars H P Murrer
Journal:  Adv Radiat Oncol       Date:  2021-02-09

5.  Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?

Authors:  Mitchell Sabloff; Steven Tisseverasinghe; Mustafa Ege Babadagli; Rajiv Samant
Journal:  Curr Oncol       Date:  2021-02-14       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.